{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:14:54Z","timestamp":1793823294698,"version":"4.6.1"},"reference-count":114,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T00:00:00Z","timestamp":1667174400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T00:00:00Z","timestamp":1667174400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Res"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1038\/s41390-022-02336-w","type":"journal-article","created":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T08:04:12Z","timestamp":1667203452000},"page":"1828-1836","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["B cell phenotype, activity, and function in idiopathic nephrotic syndrome"],"prefix":"10.1038","volume":"93","author":[{"given":"Junhan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengjun","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,31]]},"reference":[{"key":"2336_CR1","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s00281-013-0415-3","volume":"36","author":"D Sahali","year":"2014","unstructured":"Sahali, D. et al. Immunopathogenesis of idiopathic nephrotic syndrome with relapse. Semin. Immunopathol. 36, 421\u2013429 (2014).","journal-title":"Semin. Immunopathol."},{"key":"2336_CR2","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0140-6736(18)30536-1","volume":"392","author":"DG Noone","year":"2018","unstructured":"Noone, D. G., Iijima, K. & Parekh, R. Idiopathic nephrotic syndrome in children. Lancet 392, 61\u201374 (2018).","journal-title":"Lancet"},{"key":"2336_CR3","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/S0140-6736(74)91880-7","volume":"2","author":"RJ Shalhoub","year":"1974","unstructured":"Shalhoub, R. J. Pathogenesis of lipoid nephrosis: a disorder of T-cell function. Lancet 2, 556\u2013560 (1974).","journal-title":"Lancet"},{"key":"2336_CR4","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s00467-015-3082-x","volume":"31","author":"JC Davin","year":"2016","unstructured":"Davin, J. C. The glomerular permeability factors in idiopathic nephrotic syndrome. Pediatr. Nephrol. 31, 207\u2013215 (2016).","journal-title":"Pediatr. Nephrol."},{"key":"2336_CR5","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(03)14184-0","volume":"362","author":"AA Eddy","year":"2003","unstructured":"Eddy, A. A. & Symons, J. M. Nephrotic syndrome in childhood. Lancet 362, 629\u2013639 (2003).","journal-title":"Lancet"},{"key":"2336_CR6","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s10157-011-0465-6","volume":"15","author":"T Takei","year":"2011","unstructured":"Takei, T. & Nitta, K. Rituximab and minimal change nephrotic syndrome: a therapeutic option. Clin. Exp. Nephrol. 15, 641\u2013647 (2011).","journal-title":"Clin. Exp. Nephrol."},{"key":"2336_CR7","doi-asserted-by":"publisher","first-page":"710","DOI":"10.2215\/CJN.08500815","volume":"11","author":"P Ravani","year":"2016","unstructured":"Ravani, P., Bonanni, A., Rossi, R., Caridi, G. & Ghiggeri, G. M. Anti-CD20 antibodies for idiopathic nephrotic syndrome in children. Clin. J. Am. Soc. Nephrol. 11, 710\u2013720 (2016).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"2336_CR8","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1159\/000085357","volume":"25","author":"MJ Kemper","year":"2005","unstructured":"Kemper, M. J., Zepf, K., Klaassen, I., Link, A. & Muller-Wiefel, D. E. Changes of lymphocyte populations in pediatric steroid-sensitive nephrotic syndrome are more pronounced in remission than in relapse. Am. J. Nephrol. 25, 132\u2013137 (2005).","journal-title":"Am. J. Nephrol."},{"key":"2336_CR9","first-page":"705","volume":"58","author":"Q Ye","year":"2020","unstructured":"Ye, Q. & Mao, J. H. Immunologic pathogenesis of idiopathic nephrotic syndrome in children: the present and future. Zhonghua Er Ke Za Zhi 58, 705\u2013707 (2020).","journal-title":"Zhonghua Er Ke Za Zhi"},{"key":"2336_CR10","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/74139","volume":"24","author":"S Somlo","year":"2000","unstructured":"Somlo, S. & Mundel, P. Getting a foothold in nephrotic syndrome. Nat. Genet. 24, 333\u2013335 (2000).","journal-title":"Nat. Genet."},{"key":"2336_CR11","first-page":"659","volume":"35","author":"HK Lorenzo","year":"2019","unstructured":"Lorenzo, H. K. & Candelier, J. J. Syndrome n\u00e9phrotique idiopathique et facteurs circulants - une arl\u00e9sienne? [Idiopathic nephrotic syndrome: une Arl\u00e9sienne?]. Med. Sci. 35, 659\u2013666 (2019).","journal-title":"Med. Sci."},{"key":"2336_CR12","doi-asserted-by":"publisher","first-page":"4431","DOI":"10.4049\/jimmunol.151.9.4431","volume":"151","author":"DM Allman","year":"1993","unstructured":"Allman, D. M., Ferguson, S. E., Lentz, V. M. & Cancro, M. P. Peripheral B cell maturation. II. Heat-stable antigen(hi) splenic B cells are an immature developmental intermediate in the production of long-lived marrow-derived B cells. J. Immunol. 151, 4431\u20134444 (1993).","journal-title":"J. Immunol."},{"key":"2336_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-981-15-3532-1_1","volume":"1254","author":"Y Wang","year":"2020","unstructured":"Wang, Y., Liu, J., Burrows, P. D. & Wang, J. Y. B cell development and maturation. Adv. Exp. Med. Biol. 1254, 1\u201322 (2020).","journal-title":"Adv. Exp. Med. Biol."},{"key":"2336_CR14","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.coi.2008.03.014","volume":"20","author":"D Allman","year":"2008","unstructured":"Allman, D. & Pillai, S. Peripheral B cell subsets. Curr. Opin. Immunol. 20, 149\u2013157 (2008).","journal-title":"Curr. Opin. Immunol."},{"key":"2336_CR15","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.imlet.2017.06.006","volume":"188","author":"D Ribatti","year":"2017","unstructured":"Ribatti, D. The discovery of plasma cells: an historical note. Immunol. Lett. 188, 64\u201367 (2017).","journal-title":"Immunol. Lett."},{"key":"2336_CR16","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s00467-017-3677-5","volume":"33","author":"M Colucci","year":"2018","unstructured":"Colucci, M., Corpetti, G., Emma, F. & Vivarelli, M. Immunology of idiopathic nephrotic syndrome. Pediatr. Nephrol. 33, 573\u2013584 (2018).","journal-title":"Pediatr. Nephrol."},{"key":"2336_CR17","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/j.0105-2896.2004.0109.x","volume":"197","author":"R Carsetti","year":"2004","unstructured":"Carsetti, R., Rosado, M. M. & Wardmann, H. Peripheral development of B cells in mouse and man. Immunol. Rev. 197, 179\u2013191 (2004).","journal-title":"Immunol. Rev."},{"key":"2336_CR18","doi-asserted-by":"publisher","first-page":"137","DOI":"10.2215\/CJN.09430915","volume":"11","author":"W Hoffman","year":"2016","unstructured":"Hoffman, W., Lakkis, F. G. & Chalasani, G. B cells, antibodies, and more. Clin. J. Am. Soc. Nephrol. 11, 137\u2013154 (2016).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"2336_CR19","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.cimid.2012.01.008","volume":"35","author":"SM Barratt-Boyes","year":"2012","unstructured":"Barratt-Boyes, S. M. Comparative immunology, microbiology and infectious diseases. Introduction. Comp. Immunol. Microbiol. Infect. Dis. 35, 217\u2013218 (2012).","journal-title":"Comp. Immunol. Microbiol. Infect. Dis."},{"key":"2336_CR20","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1111\/imr.12640","volume":"283","author":"T Inoue","year":"2018","unstructured":"Inoue, T., Moran, I., Shinnakasu, R., Phan, T. G. & Kurosaki, T. Generation of memory B cells and their reactivation. Immunol. Rev. 283, 138\u2013149 (2018).","journal-title":"Immunol. Rev."},{"key":"2336_CR21","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.clim.2006.05.003","volume":"120","author":"H Alachkar","year":"2006","unstructured":"Alachkar, H., Taubenheim, N., Haeney, M. R., Durandy, A. & Arkwright, P. D. Memory switched B cell percentage and not serum immunoglobulin concentration is associated with clinical complications in children and adults with specific antibody deficiency and common variable immunodeficiency. Clin. Immunol. 120, 310\u2013318 (2006).","journal-title":"Clin. Immunol."},{"key":"2336_CR22","first-page":"321","volume":"17","author":"M Vodjgani","year":"2007","unstructured":"Vodjgani, M. et al. Analysis of class-switched memory B cells in patients with common variable immunodeficiency and its clinical implications. J. Investig. Allergol. Clin. Immunol. 17, 321\u2013328 (2007).","journal-title":"J. Investig. Allergol. Clin. Immunol."},{"key":"2336_CR23","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.2147\/DDDT.S302257","volume":"15","author":"L Lin","year":"2021","unstructured":"Lin, L. et al. Consolidation treatment and long-term prognosis of rituximab in minimal change disease and focal segmental glomerular sclerosis. Drug Des. Dev. Ther. 15, 1945\u20131953 (2021).","journal-title":"Drug Des. Dev. Ther."},{"key":"2336_CR24","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12882-020-01797-7","volume":"21","author":"P Hansrivijit","year":"2020","unstructured":"Hansrivijit, P., Cheungpasitporn, W., Thongprayoon, C. & Ghahramani, N. Rituximab therapy for focal segmental glomerulosclerosis and minimal change disease in adults: a systematic review and meta-analysis. BMC Nephrol. 21, 134 (2020).","journal-title":"BMC Nephrol."},{"key":"2336_CR25","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1159\/000360908","volume":"39","author":"A Kronbichler","year":"2014","unstructured":"Kronbichler, A. et al. Rituximab treatment for relapsing minimal change disease and focal segmental glomerulosclerosis: a systematic review. Am. J. Nephrol. 39, 322\u2013330 (2014).","journal-title":"Am. J. Nephrol."},{"key":"2336_CR26","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.kint.2019.09.033","volume":"97","author":"EY Chan","year":"2020","unstructured":"Chan, E. Y. et al. Both the rituximab dose and maintenance immunosuppression in steroid-dependent\/frequently-relapsing nephrotic syndrome have important effects on outcomes. Kidney Int. 97, 393\u2013401 (2020).","journal-title":"Kidney Int."},{"key":"2336_CR27","doi-asserted-by":"publisher","first-page":"835","DOI":"10.3389\/fimmu.2018.00835","volume":"9","author":"K Hofmann","year":"2018","unstructured":"Hofmann, K., Clauder, A. K. & Manz, R. A. Targeting B cells and plasma cells in autoimmune diseases. Front. Immunol. 9, 835 (2018).","journal-title":"Front. Immunol."},{"key":"2336_CR28","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1007\/s00467-013-2534-4","volume":"29","author":"G Cara-Fuentes","year":"2014","unstructured":"Cara-Fuentes, G. et al. Rituximab in idiopathic nephrotic syndrome: does it make sense? Pediatr. Nephrol. 29, 1313\u20131319 (2014).","journal-title":"Pediatr. Nephrol."},{"key":"2336_CR29","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1007\/s00262-011-1168-2","volume":"61","author":"D Stroopinsky","year":"2012","unstructured":"Stroopinsky, D., Katz, T., Rowe, J. M., Melamed, D. & Avivi, I. Rituximab-induced direct inhibition of T-cell activation. Cancer Immunol. Immunother. 61, 1233\u20131241 (2012).","journal-title":"Cancer Immunol. Immunother."},{"key":"2336_CR30","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/ped.12804","volume":"58","author":"K Suyama","year":"2016","unstructured":"Suyama, K. et al. Rituximab and low-dose cyclosporine combination therapy for steroid-resistant focal segmental glomerulosclerosis. Pediatr. Int. 58, 219\u2013223 (2016).","journal-title":"Pediatr. Int."},{"key":"2336_CR31","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/s41390-018-0088-7","volume":"84","author":"D Bhatia","year":"2018","unstructured":"Bhatia, D. et al. Rituximab modulates T- and B-lymphocyte subsets and urinary CD80 excretion in patients with steroid-dependent nephrotic syndrome. Pediatr. Res. 84, 520\u2013526 (2018).","journal-title":"Pediatr. Res."},{"key":"2336_CR32","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1002\/art.21617","volume":"54","author":"MJ Leandro","year":"2006","unstructured":"Leandro, M. J., Cambridge, G., Ehrenstein, M. R. & Edwards, J. C. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum. 54, 613\u2013620 (2006).","journal-title":"Arthritis Rheum."},{"key":"2336_CR33","doi-asserted-by":"publisher","first-page":"85ra46","DOI":"10.1126\/scitranslmed.3002231","volume":"3","author":"A Fornoni","year":"2011","unstructured":"Fornoni, A. et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci. Transl. Med. 3, 85ra46 (2011).","journal-title":"Sci. Transl. Med."},{"key":"2336_CR34","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/nep.12737","volume":"22","author":"Y Takahashi","year":"2017","unstructured":"Takahashi, Y., Ikezumi, Y. & Saitoh, A. Rituximab protects podocytes and exerts anti-proteinuric effects in rat adriamycin-induced nephropathy independent of B-lymphocytes. Nephrology 22, 49\u201357 (2017).","journal-title":"Nephrology"},{"key":"2336_CR35","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/cmi.2012.61","volume":"10","author":"Z Hua","year":"2013","unstructured":"Hua, Z. & Hou, B. TLR signaling in B-cell development and activation. Cell Mol. Immunol. 10, 103\u2013106 (2013).","journal-title":"Cell Mol. Immunol."},{"key":"2336_CR36","first-page":"151","volume":"390","author":"DA Thorley-Lawson","year":"2015","unstructured":"Thorley-Lawson, D. A. EBV persistence-introducing the virus. Curr. Top. Microbiol. Immunol. 390, 151\u2013209 (2015).","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"2336_CR37","first-page":"265","volume":"391","author":"A L\u00fcnemann","year":"2015","unstructured":"L\u00fcnemann, A., Rowe, M. & Nadal, D. Innate immune recognition of EBV. Curr. Top. Microbiol. Immunol. 391, 265\u2013287 (2015).","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"2336_CR38","doi-asserted-by":"publisher","first-page":"587380","DOI":"10.3389\/fimmu.2020.587380","volume":"11","author":"G Houen","year":"2021","unstructured":"Houen, G. & Trier, N. H. Epstein-Barr virus and systemic autoimmune diseases. Front. Immunol. 11, 587380 (2021).","journal-title":"Front. Immunol."},{"key":"2336_CR39","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/pr.2016.200","volume":"81","author":"C Dossier","year":"2017","unstructured":"Dossier, C., Jamin, A. & Desch\u00eanes, G. Idiopathic nephrotic syndrome: the EBV hypothesis. Pediatr. Res. 81, 233\u2013239 (2017).","journal-title":"Pediatr. Res."},{"key":"2336_CR40","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1111\/cei.12659","volume":"182","author":"A Jamin","year":"2015","unstructured":"Jamin, A. et al. Toll-like receptor 3 expression and function in childhood idiopathic nephrotic syndrome. Clin. Exp. Immunol. 182, 332\u2013345 (2015).","journal-title":"Clin. Exp. Immunol."},{"key":"2336_CR41","first-page":"435","volume":"2","author":"N Printza","year":"2009","unstructured":"Printza, N., Papachristou, F., Tzimouli, V., Taparkou, A. & Kanakoudi-Tsakalidou, F. Peripheral CD19+ B cells are increased in children with active steroid-sensitive nephrotic syndrome. NDT Plus 2, 435\u2013436 (2009).","journal-title":"NDT Plus"},{"key":"2336_CR42","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/1824-7288-39-42","volume":"39","author":"B Yildiz","year":"2013","unstructured":"Yildiz, B., Cetin, N., Kural, N. & Colak, O. CD19 + CD23+ B cells, CD4 + CD25+ T cells, E-selectin and interleukin-12 levels in children with steroid sensitive nephrotic syndrome. Ital. J. Pediatr. 39, 42 (2013).","journal-title":"Ital. J. Pediatr."},{"key":"2336_CR43","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1681\/ASN.2015050523","volume":"27","author":"M Colucci","year":"2016","unstructured":"Colucci, M. et al. B cell reconstitution after rituximab treatment in idiopathic nephrotic syndrome. J. Am. Soc. Nephrol. 27, 1811\u20131822 (2016).","journal-title":"J. Am. Soc. Nephrol."},{"key":"2336_CR44","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s00467-018-4095-z","volume":"34","author":"M Colucci","year":"2019","unstructured":"Colucci, M. et al. B cell phenotype in pediatric idiopathic nephrotic syndrome. Pediatr. Nephrol. 34, 177\u2013181 (2019).","journal-title":"Pediatr. Nephrol."},{"key":"2336_CR45","first-page":"954","volume":"36","author":"P Yu","year":"2020","unstructured":"Yu, P. et al. Clinical significance of B lymphocyte phenotype in children with frequent-relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome. J. Practical Med. 36, 954\u2013958 (2020) (in Chinese).","journal-title":"J. Practical Med."},{"key":"2336_CR46","doi-asserted-by":"publisher","first-page":"377","DOI":"10.3389\/fped.2019.00377","volume":"7","author":"C Ling","year":"2019","unstructured":"Ling, C. et al. Altered B-lymphocyte homeostasis in idiopathic nephrotic syndrome. Front. Pediatr. 7, 377 (2019).","journal-title":"Front. Pediatr."},{"key":"2336_CR47","doi-asserted-by":"publisher","first-page":"eabc3961","DOI":"10.1126\/scitranslmed.abc3961","volume":"13","author":"E Crickx","year":"2021","unstructured":"Crickx, E. et al. Rituximab-resistant splenic memory B cells and newly engaged na\u00efve B cells fuel relapses in patients with immune thrombocytopenia. Sci. Transl. Med. 13, eabc3961 (2021).","journal-title":"Sci. Transl. Med."},{"key":"2336_CR48","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1590\/2175-8239-jbn-2018-0254","volume":"42","author":"JE Santos","year":"2020","unstructured":"Santos, J. E. et al. Rituximab use in adult glomerulopathies and its rationale. J. Bras. Nefrol. 42, 77\u201393 (2020).","journal-title":"J. Bras. Nefrol."},{"key":"2336_CR49","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1681\/ASN.V991709","volume":"9","author":"J Dantal","year":"1998","unstructured":"Dantal, J. et al. Antihuman immunoglobulin affinity immunoadsorption strongly decreases proteinuria in patients with relapsing nephrotic syndrome. J. Am. Soc. Nephrol. 9, 1709\u20131715 (1998).","journal-title":"J. Am. Soc. Nephrol."},{"key":"2336_CR50","doi-asserted-by":"publisher","first-page":"e0136558","DOI":"10.1371\/journal.pone.0136558","volume":"10","author":"JM Thurman","year":"2015","unstructured":"Thurman, J. M. et al. Complement activation in patients with focal segmental glomerulosclerosis. PLoS ONE 10, e0136558 (2015).","journal-title":"PLoS ONE"},{"key":"2336_CR51","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1159\/000501827","volume":"44","author":"S Mirioglu","year":"2019","unstructured":"Mirioglu, S. et al. Co-deposition of IgM and C3 may indicate unfavorable renal outcomes in adult patients with primary focal segmental glomerulosclerosis. Kidney Blood Press. Res. 44, 961\u2013972 (2019).","journal-title":"Kidney Blood Press. Res."},{"key":"2336_CR52","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1681\/ASN.2012020187","volume":"24","author":"D Strassheim","year":"2013","unstructured":"Strassheim, D. et al. IgM contributes to glomerular injury in FSGS. J. Am. Soc. Nephrol. 24, 393\u2013406 (2013).","journal-title":"J. Am. Soc. Nephrol."},{"key":"2336_CR53","doi-asserted-by":"publisher","first-page":"e0234934","DOI":"10.1371\/journal.pone.0234934","volume":"15","author":"J Huang","year":"2020","unstructured":"Huang, J. et al. Complement activation profile of patients with primary focal segmental glomerulosclerosis. PLoS ONE 15, e0234934 (2020).","journal-title":"PLoS ONE"},{"key":"2336_CR54","first-page":"1890","volume":"13","author":"S Chen","year":"2021","unstructured":"Chen, S., Wang, J. & Liang, S. Clinical significance of T lymphocyte subsets, immunoglobulin and complement expression in peripheral blood of children with steroid-dependent nephrotic syndrome\/frequently relapsing nephrotic syndrome. Am. J. Transl. Res. 13, 1890\u20131895 (2021).","journal-title":"Am. J. Transl. Res."},{"key":"2336_CR55","doi-asserted-by":"publisher","first-page":"3728","DOI":"10.19082\/3728","volume":"9","author":"GM El Mashad","year":"2017","unstructured":"El Mashad, G. M., El Hady Ibrahim, S. A. & Abdelnaby, S. A. A. Immunoglobulin G and M levels in childhood nephrotic syndrome: two centers Egyptian study. Electron Physician 9, 3728\u20133732 (2017).","journal-title":"Electron Physician"},{"key":"2336_CR56","doi-asserted-by":"publisher","first-page":"186","DOI":"10.4103\/0971-4065.82638","volume":"21","author":"DM Youssef","year":"2011","unstructured":"Youssef, D. M., Salam, S. M. & Karam, R. A. Prediction of steroid response in nephrotic syndrome by humoral immunity assessment. Indian J. Nephrol. 21, 186\u2013190 (2011).","journal-title":"Indian J. Nephrol."},{"key":"2336_CR57","first-page":"64","volume":"27","author":"A Ahmed","year":"2011","unstructured":"Ahmed, A. et al. Low serum IgG level during remission: a predictor of frequent relapse nephrotic syndrome. DS (Child) HJ 27, 64\u201367 (2011).","journal-title":"DS (Child) HJ"},{"key":"2336_CR58","first-page":"110","volume":"70","author":"H Yokoyama","year":"1987","unstructured":"Yokoyama, H. et al. Impaired immunoglobulin G production in minimal change nephrotic syndrome in adults. Clin. Exp. Immunol. 70, 110\u2013115 (1987).","journal-title":"Clin. Exp. Immunol."},{"key":"2336_CR59","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s00467-012-2361-z","volume":"28","author":"L Delbe-Bertin","year":"2013","unstructured":"Delbe-Bertin, L., Aoun, B., Tudorache, E., Lapillone, H. & Ulinski, T. Does rituximab induce hypogammaglobulinemia in patients with pediatric idiopathic nephrotic syndrome? Pediatr. Nephrol. 28, 447\u2013451 (2013).","journal-title":"Pediatr. Nephrol."},{"key":"2336_CR60","first-page":"590","volume":"51","author":"HK Yap","year":"1983","unstructured":"Yap, H. K. et al. The incidence of atopy in steroid-responsive nephrotic syndrome: Clinical and immunological parameters. Ann. Allergy 51, 590\u2013594 (1983).","journal-title":"Ann. Allergy"},{"key":"2336_CR61","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1053\/j.ajkd.2009.03.019","volume":"54","author":"M Abdel-Hafez","year":"2009","unstructured":"Abdel-Hafez, M., Shimada, M., Lee, P. Y., Johnson, R. J. & Garin, E. H. Idiopathic nephrotic syndrome and atopy: is there a common link? Am. J. Kidney Dis. 54, 945\u2013953 (2009).","journal-title":"Am. J. Kidney Dis."},{"key":"2336_CR62","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1007\/s10157-010-0330-z","volume":"14","author":"T Kanai","year":"2010","unstructured":"Kanai, T. et al. Th2 cells predominate in idiopathic steroid-sensitive nephrotic syndrome. Clin. Exp. Nephrol. 14, 578\u2013583 (2010).","journal-title":"Clin. Exp. Nephrol."},{"key":"2336_CR63","doi-asserted-by":"publisher","first-page":"3480309","DOI":"10.1155\/2018\/3480309","volume":"2018","author":"CC Hsiao","year":"2018","unstructured":"Hsiao, C. C. et al. Immunoglobulin E and G levels in predicting minimal change disease before renal biopsy. Biomed. Res. Int. 2018, 3480309 (2018).","journal-title":"Biomed. Res. Int."},{"key":"2336_CR64","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/j.1365-2249.2005.02862.x","volume":"141","author":"L Musante","year":"2005","unstructured":"Musante, L. et al. Circulating anti-actin and anti-ATP synthase antibodies identify a sub-set of patients with idiopathic nephrotic syndrome. Clin. Exp. Immunol. 141, 491\u2013499 (2005).","journal-title":"Clin. Exp. Immunol."},{"key":"2336_CR65","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.jaut.2017.12.014","volume":"89","author":"A Jamin","year":"2018","unstructured":"Jamin, A. et al. Autoantibodies against podocytic UCHL1 are associated with idiopathic nephrotic syndrome relapses and induce proteinuria in mice. J. Autoimmun. 89, 149\u2013161 (2018).","journal-title":"J. Autoimmun."},{"key":"2336_CR66","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1681\/ASN.2021060794","volume":"33","author":"AJB Watts","year":"2022","unstructured":"Watts, A. J. B. et al. Discovery of autoantibodies targeting nephrin in minimal change disease supports a novel autoimmune etiology. J. Am. Soc. Nephrol. 33, 238\u2013252 (2022).","journal-title":"J. Am. Soc. Nephrol."},{"key":"2336_CR67","doi-asserted-by":"publisher","unstructured":"Hada, I. et al. A novel mouse model of idiopathic nephrotic syndrome induced by immunization with the podocyte protein Crb2. J. Am. Soc. Nephrol. https:\/\/doi.org\/10.1681\/ASN.2022010070 (2022).","DOI":"10.1681\/ASN.2022010070"},{"key":"2336_CR68","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1084\/jem.189.10.1639","volume":"189","author":"OT Chan","year":"1999","unstructured":"Chan, O. T., Hannum, L. G., Haberman, A. M., Madaio, M. P. & Shlomchik, M. J. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J. Exp. Med. 189, 1639\u20131648 (1999).","journal-title":"J. Exp. Med."},{"key":"2336_CR69","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1002\/art.20858","volume":"52","author":"PP Sfikakis","year":"2005","unstructured":"Sfikakis, P. P. et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum. 52, 501\u2013513 (2005).","journal-title":"Arthritis Rheum."},{"key":"2336_CR70","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1111\/j.1600-6143.2006.01288.x","volume":"6","author":"MD Pescovitz","year":"2006","unstructured":"Pescovitz, M. D. Rituximab, an anti-CD20 monoclonal antibody: History and mechanism of action. Am. J. Transpl. 6, 859\u2013866 (2006).","journal-title":"Am. J. Transpl."},{"key":"2336_CR71","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/imr.12859","volume":"296","author":"Z Hua","year":"2020","unstructured":"Hua, Z. & Hou, B. The role of B cell antigen presentation in the initiation of CD4+ T cell response. Immunol. Rev. 296, 24\u201335 (2020).","journal-title":"Immunol. Rev."},{"key":"2336_CR72","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1111\/cei.13537","volume":"203","author":"P Alonso-Guallart","year":"2021","unstructured":"Alonso-Guallart, P. et al. CD40L-stimulated B cells for ex-vivo expansion of polyspecific non-human primate regulatory T cells for translational studies. Clin. Exp. Immunol. 203, 480\u2013492 (2021).","journal-title":"Clin. Exp. Immunol."},{"key":"2336_CR73","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1111\/ped.14005","volume":"61","author":"FK Eroglu","year":"2019","unstructured":"Eroglu, F. K. et al. CD80 expression and infiltrating regulatory T cells in idiopathic nephrotic syndrome of childhood. Pediatr. Int. 61, 1250\u20131256 (2019).","journal-title":"Pediatr. Int."},{"key":"2336_CR74","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1182\/blood-2017-06-741033","volume":"131","author":"B Rowshanravan","year":"2018","unstructured":"Rowshanravan, B., Halliday, N. & Sansom, D. M. CTLA-4: a moving target in immunotherapy. Blood 131, 58\u201367 (2018).","journal-title":"Blood"},{"key":"2336_CR75","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s40348-021-00128-6","volume":"8","author":"A Hackl","year":"2021","unstructured":"Hackl, A. et al. The role of the immune system in idiopathic nephrotic syndrome. Mol. Cell Pediatr. 8, 18 (2021).","journal-title":"Mol. Cell Pediatr."},{"key":"2336_CR76","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1111\/ped.14294","volume":"62","author":"N Chebotareva","year":"2020","unstructured":"Chebotareva, N., Bobkova, I. & Lysenko, L. T regulatory cells in renal tissue of patients with nephrotic syndrome. Pediatr. Int. 62, 884\u2013885 (2020).","journal-title":"Pediatr. Int."},{"key":"2336_CR77","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1111\/ped.13255","volume":"59","author":"S Tsuji","year":"2017","unstructured":"Tsuji, S. et al. Regulatory T cells and CTLA-4 in idiopathic nephrotic syndrome. Pediatr. Int. 59, 643\u2013646 (2017).","journal-title":"Pediatr. Int."},{"key":"2336_CR78","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.4103\/1319-2442.338276","volume":"32","author":"SC Tun\u00e7ay","year":"2021","unstructured":"Tun\u00e7ay, S. C., Hakverdi, G., \u015eenol, \u00d6. & Mir, S. Regulatory T-cell changes in patients with steroid-resistant nephrotic syndrome after rituximab therapy. Saudi J. Kidney Dis. Transpl. 32, 1028\u20131033 (2021).","journal-title":"Saudi J. Kidney Dis. Transpl."},{"key":"2336_CR79","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.jped.2017.08.005","volume":"94","author":"FTL Guimar\u00e3es","year":"2018","unstructured":"Guimar\u00e3es, F. T. L. et al. T-lymphocyte-expressing inflammatory cytokines underlie persistence of proteinuria in children with idiopathic nephrotic syndrome. J. Pediatr. 94, 546\u2013553 (2018).","journal-title":"J. Pediatr."},{"key":"2336_CR80","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.clim.2011.02.018","volume":"139","author":"LL Liu","year":"2011","unstructured":"Liu, L. L. et al. Th17\/Treg imbalance in adult patients with minimal change nephrotic syndrome. Clin. Immunol. 139, 314\u2013320 (2011).","journal-title":"Clin. Immunol."},{"key":"2336_CR81","doi-asserted-by":"publisher","first-page":"187","DOI":"10.15171\/jnp.2017.32","volume":"6","author":"M Stangou","year":"2017","unstructured":"Stangou, M. et al. Impact of \u03a4h1 and \u03a4h2 cytokines in the progression of idiopathic nephrotic syndrome due to focal segmental glomerulosclerosis and minimal change disease. J. Nephropathol. 6, 187\u2013195 (2017).","journal-title":"J. Nephropathol."},{"key":"2336_CR82","first-page":"612","volume":"40","author":"R Wang","year":"2021","unstructured":"Wang, R. et al. Effects of rituximab on T lymphocyte subsets and urinary CD80 levels in children with hormone-dependent nephrotic syndrome. J. Southeast Univ. (Med. Ed.) 40, 612\u2013617 (2021) (in Chinese).","journal-title":"J. Southeast Univ. (Med. Ed.)"},{"key":"2336_CR83","doi-asserted-by":"publisher","first-page":"726428","DOI":"10.3389\/fimmu.2021.726428","volume":"12","author":"M Fribourg","year":"2021","unstructured":"Fribourg, M. et al. CyTOF-enabled analysis identifies class-switched B cells as the main lymphocyte subset associated with disease relapse in children with idiopathic nephrotic syndrome. Front. Immunol. 12, 726428 (2021).","journal-title":"Front. Immunol."},{"key":"2336_CR84","doi-asserted-by":"publisher","first-page":"4801","DOI":"10.4049\/jimmunol.0902385","volume":"184","author":"R Watanabe","year":"2010","unstructured":"Watanabe, R. et al. Regulatory B cells (B 10 cells) have a suppressive role in murine lupus: CD19 and B10 cell deficiency exacerbares sysremic autoimmunity. J. Immunol. 184, 4801\u20134809 (2010).","journal-title":"J. Immunol."},{"key":"2336_CR85","doi-asserted-by":"publisher","first-page":"e0188045","DOI":"10.1371\/journal.pone.0188045","volume":"12","author":"S Doublier","year":"2017","unstructured":"Doublier, S. et al. Soluble CD40 ligand directly alters glomerular permeability and may act as a circulating permeability factor in FSGS. PLoS ONE 12, e0188045 (2017).","journal-title":"PLoS ONE"},{"key":"2336_CR86","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/S0167-5699(97)01080-3","volume":"18","author":"V Pistoia","year":"1997","unstructured":"Pistoia, V. Production of cytokines by human B cells in health and disease. Immunol. Today 18, 343\u2013350 (1997).","journal-title":"Immunol. Today"},{"key":"2336_CR87","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41581-018-0074-7","volume":"15","author":"K Oleinika","year":"2019","unstructured":"Oleinika, K., Mauri, C. & Salama, A. D. Effector and regulatory B cells in immune-mediated kidney disease. Nat. Rev. Nephrol. 15, 11\u201326 (2019).","journal-title":"Nat. Rev. Nephrol."},{"key":"2336_CR88","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/978-981-15-3532-1_8","volume":"1254","author":"L Wang","year":"2020","unstructured":"Wang, L., Fu, Y. & Chu, Y. Regulatory B cells. Adv. Exp. Med. Biol. 1254, 87\u2013103 (2020).","journal-title":"Adv. Exp. Med. Biol."},{"key":"2336_CR89","unstructured":"Yang, H. The Role and Mechanism of Regulatory B Cells in Th17\/Treg Immune Imbalance in Children with Primary Nephrotic Syndrome (Chongqing Medical University, 2016)."},{"key":"2336_CR90","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.jdermsci.2018.11.008","volume":"93","author":"T Matsushita","year":"2019","unstructured":"Matsushita, T. Regulatory and effector B cells: friends or foes? J. Dermatol. Sci. 93, 2\u20137 (2019).","journal-title":"J. Dermatol. Sci."},{"key":"2336_CR91","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/j.1651-2227.2007.00154.x","volume":"96","author":"ME Salsano","year":"2007","unstructured":"Salsano, M. E. et al. Atopy in childhood idiopathic nephrotic syndrome. Acta Paediatr. 96, 561\u2013566 (2007).","journal-title":"Acta Paediatr."},{"key":"2336_CR92","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1159\/000013420","volume":"19","author":"K Matsumoto","year":"1999","unstructured":"Matsumoto, K., Ohi, H. & Kanmatsuse, K. Interleukin-4 cooperates with interleukin-10 to inhibit vascular permeability factor release by peripheral blood mononuclear cells from patients with minimal-change nephrotic syndrome. Am. J. Nephrol. 19, 21\u201327 (1999).","journal-title":"Am. J. Nephrol."},{"key":"2336_CR93","doi-asserted-by":"publisher","first-page":"475","DOI":"10.21037\/tau-20-665","volume":"10","author":"Y Zheng","year":"2021","unstructured":"Zheng, Y., Hou, L., Wang, X. L., Zhao, C. G. & Du, Y. A review of nephrotic syndrome and atopic diseases in children. Transl. Androl. Urol. 10, 475\u2013482 (2021).","journal-title":"Transl. Androl. Urol."},{"key":"2336_CR94","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1093\/ckj\/sfaa247","volume":"14","author":"N Roca","year":"2021","unstructured":"Roca, N. et al. Activation of the acute inflammatory phase response in idiopathic nephrotic syndrome: association with clinicopathological phenotypes and with response to corticosteroids. Clin. Kidney J. 14, 1207\u20131215 (2021).","journal-title":"Clin. Kidney J."},{"key":"2336_CR95","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.cyto.2014.12.028","volume":"72","author":"N Prasad","year":"2015","unstructured":"Prasad, N. et al. Differential alteration in peripheral T-regulatory and T-effector cells with change in P-glycoprotein expression in Childhood Nephrotic Syndrome: a longitudinal study. Cytokine 72, 190\u2013196 (2015).","journal-title":"Cytokine"},{"key":"2336_CR96","doi-asserted-by":"publisher","first-page":"17050","DOI":"10.1002\/jcp.28445","volume":"234","author":"AG Shabgah","year":"2019","unstructured":"Shabgah, A. G., Shariati-Sarabi, Z., Tavakkol-Afshari, J. & Mohammadi, M. The role of BAFF and APRIL in rheumatoid arthritis. J. Cell Physiol. 234, 17050\u201317063 (2019).","journal-title":"J. Cell Physiol."},{"key":"2336_CR97","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/imr.12810","volume":"292","author":"SW Jackson","year":"2019","unstructured":"Jackson, S. W. & Davidson, A. BAFF inhibition in SLE-Is tolerance restored? Immunol. Rev. 292, 102\u2013119 (2019).","journal-title":"Immunol. Rev."},{"key":"2336_CR98","doi-asserted-by":"publisher","first-page":"102736","DOI":"10.1016\/j.autrev.2020.102736","volume":"20","author":"T M\u00f6ckel","year":"2021","unstructured":"M\u00f6ckel, T., Basta, F., Weinmann-Menke, J. & Schwarting, A. B cell activating factor (BAFF): structure, functions, autoimmunity and clinical implications in systemic lupus erythematosus (SLE). Autoimmun. Rev. 20, 102736 (2021).","journal-title":"Autoimmun. Rev."},{"key":"2336_CR99","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1111\/all.14704","volume":"76","author":"C Kaegi","year":"2021","unstructured":"Kaegi, C., Steiner, U. C., Wuest, B., Crowley, C. & Boyman, O. Systematic review of safety and efficacy of belimumab in treating immune-mediated disorders. Allergy 76, 2673\u20132683 (2021).","journal-title":"Allergy"},{"key":"2336_CR100","doi-asserted-by":"publisher","first-page":"eaas9944","DOI":"10.1126\/sciadv.aas9944","volume":"4","author":"T Matsushita","year":"2018","unstructured":"Matsushita, T. et al. BAFF inhibition attenuates fibrosis in scleroderma by modulating the regulatory and effector B cell balance. Sci. Adv. 4, eaas9944 (2018).","journal-title":"Sci. Adv."},{"key":"2336_CR101","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1146\/annurev.immunol.21.120601.141152","volume":"21","author":"F Mackay","year":"2003","unstructured":"Mackay, F., Schneider, P., Rennert, P. & Browning, J. BAFF AND APRIL: a tutorial on B cell survival. Annu. Rev. Immunol. 21, 231\u2013264 (2003).","journal-title":"Annu. Rev. Immunol."},{"key":"2336_CR102","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1146\/annurev-immunol-041015-055531","volume":"35","author":"F Weisel","year":"2017","unstructured":"Weisel, F. & Shlomchik, M. Memory B cells of mice and humans. Annu. Rev. Immunol. 35, 255\u2013284 (2017).","journal-title":"Annu. Rev. Immunol."},{"key":"2336_CR103","doi-asserted-by":"publisher","first-page":"e20191393","DOI":"10.1084\/jem.20191393","volume":"218","author":"J M\u00fcller-Winkler","year":"2021","unstructured":"M\u00fcller-Winkler, J. et al. Critical requirement for BCR, BAFF, and BAFFR in memory B cell survival. J. Exp. Med. 218, e20191393 (2021).","journal-title":"J. Exp. Med."},{"key":"2336_CR104","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.smim.2006.04.006","volume":"18","author":"C Bossen","year":"2006","unstructured":"Bossen, C. & Schneider, P. BAFF, APRIL and their receptors: structure, function and signaling. Semin. Immunol. 18, 263\u2013275 (2006).","journal-title":"Semin. Immunol."},{"key":"2336_CR105","doi-asserted-by":"publisher","first-page":"3258","DOI":"10.4049\/jimmunol.1800393","volume":"201","author":"SW Du","year":"2018","unstructured":"Du, S. W., Jacobs, H. M., Arkatkar, T., Rawlings, D. J. & Jackson, S. W. Integrated B cell, Toll-like, and BAFF receptor signals promote autoantibody production by transitional B cells. J. Immunol. 201, 3258\u20133268 (2018).","journal-title":"J. Immunol."},{"key":"2336_CR106","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1093\/ndt\/gfaa279","volume":"36","author":"J Oniszczuk","year":"2021","unstructured":"Oniszczuk, J. et al. Circulating plasmablasts and high level of BAFF are hallmarks of minimal change nephrotic syndrome in adults. Nephrol. Dial. Transpl. 36, 609\u2013617 (2021).","journal-title":"Nephrol. Dial. Transpl."},{"key":"2336_CR107","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.cyto.2010.12.004","volume":"53","author":"MR Pranzatelli","year":"2011","unstructured":"Pranzatelli, M. R., Tate, E. D., Travelstead, A. L. & Verhulst, S. J. Chemokine\/cytokine profiling after rituximab: reciprocal expression of BCA-1\/CXCL13 and BAFF in childhood OMS. Cytokine 53, 384\u2013389 (2011).","journal-title":"Cytokine"},{"key":"2336_CR108","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.immuni.2018.06.012","volume":"49","author":"J Shi","year":"2018","unstructured":"Shi, J. et al. PD-1 controls follicular T helper cell positioning and function. Immunity 49, 264\u2013274.e4 (2018).","journal-title":"Immunity"},{"key":"2336_CR109","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1111\/all.12878","volume":"71","author":"G Varricchi","year":"2016","unstructured":"Varricchi, G. et al. T follicular helper (TFH) cells in normal immune responses and in allergic disorders. Allergy 71, 1086\u20131094 (2016).","journal-title":"Allergy"},{"key":"2336_CR110","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1146\/annurev-immunol-031210-101400","volume":"29","author":"S Crotty","year":"2011","unstructured":"Crotty, S. Follicular helper CD4 T cells (TFH). Annu. Rev. Immunol. 29, 621\u2013663 (2011).","journal-title":"Annu. Rev. Immunol."},{"key":"2336_CR111","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1084\/jem.20081886","volume":"206","author":"MA Linterman","year":"2009","unstructured":"Linterman, M. A. et al. Follicular helper T cells are required for systemic autoimmunity. J. Exp. Med. 206, 561\u2013576 (2009).","journal-title":"J. Exp. Med."},{"key":"2336_CR112","doi-asserted-by":"publisher","first-page":"836157","DOI":"10.1155\/2014\/836157","volume":"2014","author":"N Zhang","year":"2014","unstructured":"Zhang, N. et al. A higher frequency of CD4+CXCR5+ T follicular helper cells in adult patients with minimal change disease. Biomed. Res. Int. 2014, 836157 (2014).","journal-title":"Biomed. Res. Int."},{"key":"2336_CR113","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.molimm.2017.12.020","volume":"94","author":"T Li","year":"2018","unstructured":"Li, T. et al. Increased PD-1+CD154+ TFH cells are possibly the most important functional subset of PD-1+ T follicular helper cells in adult patients with minimal change disease. Mol. Immunol. 94, 98\u2013106 (2018).","journal-title":"Mol. Immunol."},{"key":"2336_CR114","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jaut.2016.11.002","volume":"77","author":"S Audia","year":"2017","unstructured":"Audia, S. et al. B cell depleting therapy regulates splenic and circulating T follicular helper cells in immune thrombocytopenia. J. Autoimmun. 77, 89\u201395 (2017).","journal-title":"J. Autoimmun."}],"container-title":["Pediatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41390-022-02336-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-022-02336-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-022-02336-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T17:04:07Z","timestamp":1688144647000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41390-022-02336-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,31]]},"references-count":114,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["2336"],"URL":"https:\/\/doi.org\/10.1038\/s41390-022-02336-w","relation":{},"ISSN":["0031-3998","1530-0447"],"issn-type":[{"value":"0031-3998","type":"print"},{"value":"1530-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,31]]},"assertion":[{"value":"4 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}